Kahn Swick & Foti, LLC (“KSF”), along with its partner and former Louisiana Attorney General Charles C. Foti, Jr., has alerted investors of Ultragenyx Pharmaceutical Inc. (“Ultragenyx” or the “Company”) about a filed class action securities lawsuit.

Class Definition: The legal action aims to recover losses for investors who purchased Ultragenyx securities and were negatively impacted by alleged securities fraud occurring between August 3, 2023, and December 26, 2025. Additional details are available at: https://www.ksfcounsel.com/cases/nasdaqgs-rare/

Investors can reach out to KSF Managing Partner Lewis Kahn by calling 1-877-515-1850 or by emailing lewis.kahn@ksfcounsel.com . More information can also be found on the case webpage linked above.

Case Details: On December 26, 2025, Ultragenyx released results from its Phase 3 Orbit and Cosmic trials evaluating setrusumab (UX143) for the treatment of osteogenesis imperfecta. The company reported that neither study achieved a statistically significant reduction in annualized fracture rates. Following this outcome, Ultragenyx stated it would reassess its operational plans and implement substantial cost-cutting measures.

After the announcement, Ultragenyx’s stock price dropped sharply—falling about 42% from $34.19 per share on December 26, 2025, to $19.72 per share on December 29, 2025.

The lawsuit is titled Steven Bailey v. Ultragenyx Pharmaceutical Inc., et al., Case No. 26-cv-01097.

What to Do: Investors who experienced losses during the specified period may seek appointment as lead plaintiff by April 6, 2026. However, participation in any potential recovery does not depend on serving in that role.

• The Phase 3 clinical trials for DCCR—its sole commercial product intended to treat hyperphagia in individuals with Prader-Willi syndrome (PWS)—allegedly downplayed, misrepresented, or omitted significant evidence of safety concerns, including signs of excessive fluid retention in participants.
• As a result, the treatment may have posed greater safety risks than what the company disclosed publicly.
• Consequently, DCCR’s commercial prospects were potentially overstated, while risks such as adverse side effects, higher discontinuation rates, reduced patient uptake, physician hesitation, possible regulatory challenges, and reputational or legal consequences were not fully revealed.

Kahn Swick & Foti, LLC (KSF), along with its partner Charles C. Foti Jr., has alerted investors of Navan, Inc about a securities class action lawsuit filed against the company.

Class Definition
The legal action aims to recover losses for investors who purchased Navan shares through or traceable to the Registration Statement and Prospectus (together referred to as the “Offering Documents”) issued for the company’s October 2025 initial public offering (IPO). Individuals seeking additional details or wishing to speak with a member of the legal team can visit: https://www.ksfcounsel.com/cases/nasdaqgs-navn/

Navan investors may also reach out to KSF Managing Partner Lewis Kahn by calling 1-877-515-1850 or emailing lewis.kahn@ksfcounsel.com for further information about the case.

Case Details
The complaint alleges that Navan and certain company executives failed to disclose important information in the Offering Documents, potentially breaching federal securities laws. Specifically, the filing claims that the documents omitted or misrepresented key facts, including a substantial rise in the company’s “sales and marketing” expenses. For the quarter ending October 31, 2025, those costs reportedly climbed to nearly $95 million—an increase of about 39% compared with $68.5 million recorded in the quarter ending July 31, 2025. According to the lawsuit, once this information became public, Navan’s share price dropped significantly.

The case is titled McCown v. Navan, Inc., Case No. 26-cv-01550.

Next Steps for Investors
Investors who bought Navan securities during the relevant period and experienced financial losses have until April 24, 2026 to ask the court to appoint them as the lead plaintiff. Participation in any potential settlement or recovery, however, does not require serving in that role.

1. Its ability to effectively manage channel inventory levels.
2. Its capacity to mitigate the financial impact of the termination of the Residential Clean Energy Credit under Section 25D of the Internal Revenue Code.
3. The resulting effect on the company’s financial outlook and operational performance, which investors claim was overstated.